Document Detail

Reproducibility of successful drug trials in patients with inducible sustained ventricular tachycardia.
MedLine Citation:
PMID:  1372724     Owner:  NLM     Status:  MEDLINE    
Patients whose inducible sustained ventricular tachycardia is suppressed during serial electrophysiological testing have a small but gradually increasing actuarial incidence of recurrent arrhythmias despite therapy with the "successful" drug. In an effort to improve the predictive value of a drug response, in 1990 we began to require that our full stimulation protocol be repeated successfully several times before considering a drug to be effective. In 23 consecutive patients who had inducible sustained ventricular tachycardia which was suppressed by at least one drug during invasive serial drug testing using a standard stimulation protocol, the identical stimulation protocol was performed six times during therapy with the initially successful drug (three trials on Day 1 and three trials on Day 2). Repeat trials were completed (i.e., either all six trials were successfully finished or sustained tachycardia was induced) for 29 initially successful drugs in these 23 patients. With 18 of these 29 initially successful drugs (62%), sustained ventricular tachycardia was eventually induced during repeat trials. The eventual drug failures could not be correlated with specific drugs tested, subtherapeutic or falling serum drug levels, marked fluctuations in autonomic tone, or changes in anatomic substrate. The proportion of patients failing each repeat trial was relatively constant: 4/29 (14%) failed Trial 2, 2/25 (8%) failed Trial 3, 7/23 (30%) failed Trial 4, 2/16 (13%) failed Trial 5, and 3/14 (21%) failed Trial 6. The increase in the cumulative incidence of drug failure during repeat trials was nearly linear. Inducibility of ventricular tachycardia appears to be a probability function; a successful drug study should not be regarded as an absolute phenomenon.
R N Fogoros; J J Elson; C A Bonnet; S B Fiedler; J G Chenarides
Related Documents :
11836844 - Innovative antineoplastic agents.
1914074 - Chemotherapy in malignant mesothelioma: a review.
18590824 - The disease modifying osteoarthritis drug (dmoad): is it in the horizon?
18506674 - Response of citrus peelminer marmara gulosa guill?n and davis (lepidoptera: gracillarii...
20888084 - Characteristics of known drug space. natural products, their derivatives and synthetic ...
11324134 - Cardiovascular drugs and dental considerations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  15     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-04-30     Completed Date:  1992-04-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  295-303     Citation Subset:  IM    
Division of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Drug Evaluation
Middle Aged
Reproducibility of Results
Tachycardia / drug therapy*
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Should a VVIR pacemaker increase the heart rate with standing?
Next Document:  Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the...